The collaboration brings together ContextVision’s expertise in ultrasound image processing with BeamWorks’ deep learning platform. The companies aim to conduct joint R&D projects to develop and commercialize ultrasound-based digital biomarkers that support point-of-care clinical decision-making.

In 2025, ContextVision initiated a quantitative ultrasound program to identify a multiparameter biomarker for screening and staging of metabolic dysfunction-associated steatotic liver disease (MASLD). As part of the initiative, ContextVision set up several partnerships to augment its technical and clinical expertise in ultrasound imaging. Also in 2025, BeamWorks launched its first product line, the CadAI series (CadAI-B for breast and CadAI-T for thyroid). These on-device real-time AI solutions support ultrasound diagnostics by detecting suspicious lesions and assisting clinicians with lesion categorization as well as malignancy scoring. Through their collaboration, ContextVision and BeamWorks aim to leverage their respective capabilities and portfolios to co-develop and commercialize AI-powered quantitative ultrasound solutions, focused on MASLD, breast cancer, thyroid nodule screening, as well as across additional clinical applications.

“We are excited to collaborate with ContextVision, a recognized global leader in medical imaging software,” said Jaeil Kim and Won Hwa Kim, Co-CEOs of BeamWorks Inc. “This partnership combines our deep learning AI platform with ContextVision’s ultrasound imaging chain expertise, creating new opportunities to advance quantitative ultrasound technologies and support clinicians with improved diagnostic capabilities.”

“Strategic collaborations are a key part of expanding our portfolio with quantitative imaging solutions, offering our customer base new solutions with significant value propositions in aiding diagnostic accuracy and treatment monitoring” said Gerald Pötzsch, CEO of ContextVision. “BeamWorks brings strong expertise in AI-based medical image analysis. By combining our technologies, we aim to accelerate the development of quantitative ultrasound imaging solutions that can deliver meaningful diagnostic insights directly at the point-of-care.”

For more information, please contact:
Gerald Pötzsch
Chief Executive Officer, ContextVision AB
gerald.potzsch@contextvision.com
 
About ContextVision
ContextVision is a software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-ray and MRI equipment around the world. Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment. The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker CONTX.

About BeamWorks
BeamWorks is a company founded in 2021 by radiology experts and AI specialists, and is headquartered in Daegu, South Korea. Leveraging its proprietary deep learning technology, BeamWorks has developed and successfully commercialized an on-device, real-time AI diagnostic support system that assists ultrasound examinations critical to breast cancer and thyroid assessment. With this commercialization, the company has established a strong position in ultrasound-focused medical imaging AI, and is expanding its business with global regulatory market clearances. In particular, by reducing reliance on high-performance computing resources, BeamWorks seeks to enable ultrasound-based diagnostic use in regions with limited access to advanced healthcare resources, helping address gaps in accessibility to care.